Director, Cell Therapy and Cell Engineering Facility, Memorial Sloan Kettering Cancer
Dr Rivière joined the faculty of the Memorial Sloan-Kettering Cancer Center (MSKCC) in
1999. She is currently the Director of the Cell Therapy and Cell Engineering Facility where
she investigates novel strategies for cell therapies and immunotherapies to increase or retarget
the immune response against tumors and treat hematological disorders. Her laboratory
has developed multiple processes for clinical-grade gamma-retroviral and lentiviral vector
production as well as hematopoietic and T-cell manufacturing.
Chief GMP Manufacturing and Chief Medical Officer, Cartesian Therapeutics
Metin Kurtoglu, MD, PhD, is a medical oncologist board certified in internal medicine. Dr
Kurtoglu’s clinical and basic science research career spans over 20 years and has focused
on developing novel targets for drug-resistant cancer cells and cancer stem cells, including
multiple myeloma. He has also been an investigator in various cancer immunotherapy trials.
Cartesian Therapeutics is pioneering RNA cell therapies in and beyond oncology, with three
assets in clinical trials for autoimmune, oncologic and respiratory disorders. The investigational
therapies are manufactured at Cartesian’s cGMP manufacturing facility.
Head of Cell and Gene Therapy Segment Marketing at Lonza Bioscience Solutions
Tariq Haq is Head of Cell and Gene Therapy Segment Marketing at Lonza Bioscience Solutions. He brings with
him extensive bioprocess experience including strategy development, new product launch
and commercialization. Previously he has held positions in marketing and product management
while working in companies such as Pall, GE Healthcare, Thermo Fisher Scientific
and Millipore. He has authored publications in peer-reviewed journals such as Science and
Vaccine. Tariq holds degrees in Physics and Biotechnology from Aligarh Muslim University in
India and in Biochemistry from Texas A&M University in the US.